Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia.

Vercueil C, Eberst L, Humbrecht C, Fornecker LM

Open source

DOI
10.1097/hs9.0000000000000655
Published
2021 Dec
Container
HemaSphere
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/hs9.0000000000000655,
  title = {Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia.},
  author = {Vercueil C and Eberst L and Humbrecht C and Fornecker LM},
  year = {2021},
  journal = {HemaSphere},
  doi = {10.1097/hs9.0000000000000655},
  url = {https://doi.org/10.1097/hs9.0000000000000655}
}

RIS

TY  - JOUR
TI  - Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia.
AU  - Vercueil C
AU  - Eberst L
AU  - Humbrecht C
AU  - Fornecker LM
PY  - 2021
JO  - HemaSphere
DO  - 10.1097/hs9.0000000000000655
UR  - https://doi.org/10.1097/hs9.0000000000000655
ER  - 

APA

C, V., L, E., C, H., & LM, F. (2021). Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia.. HemaSphere. https://doi.org/10.1097/hs9.0000000000000655

Source records